Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.
Keywords: colorectal cancer; long‐term survival; regorafenib.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.